Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

LIGAND PHARMACEUTICALS INC Director's Dealing 2016

Feb 17, 2016

31289_dirs_2016-02-16_9d501b75-9115-4795-951b-9231ee9ac76f.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: LIGAND PHARMACEUTICALS INC (LGND)
CIK: 0000886163
Period of Report: 2016-02-11

Reporting Person: Berkman Charles S (VP, Gen. Counsel & Secretary)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2016-02-11 Common Stock A 2193.0 $0.0 Acquired 29647 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2016-02-11 Employee Stock Option (right to buy) $85.79 A 10463.0 Acquired 2026-02-11 Common Stock (10463) Direct

Footnotes

F1: Grant to reporting person of options to purchase shares of common stock ("Option Shares"), exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 02/11/16.